This trial is looking at how a new drug affects teenagers with Hereditary Angioedema.
3 Primary · 0 Secondary · Reporting Duration: Up to 6 hours after IMP administration
Experimental Treatment
12 Total Participants · 1 Treatment Group
Primary Treatment: KVD900 600 mg · No Placebo Group · Phase 3
Age 12 - 17 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: